🚀 VC round data is live in beta, check it out!
GoodRx Valuation Multiples
Discover revenue and EBITDA valuation multiples for GoodRx and similar public comparables like CEWE Group, Zjamp Group, Genky Drug Stores, Nerdwallet and more.
GoodRx Overview
About GoodRx
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Founded
2015
HQ
Employees
738
Website
Sectors
Financials (LTM)
EV
$1B
GoodRx Financials
GoodRx reported last 12-month revenue of $788M and EBITDA of $261M.
In the same LTM period, GoodRx generated $728M in gross profit, $261M in EBITDA, and $31M in net income.
Revenue (LTM)
GoodRx P&L
In the most recent fiscal year, GoodRx reported revenue of $797M and EBITDA of $271M.
GoodRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $788M | XXX | $797M | XXX | XXX | XXX |
| Gross Profit | $728M | XXX | $739M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $261M | XXX | $271M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $31M | XXX | $30M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | — | — | $226M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GoodRx Stock Performance
GoodRx has current market cap of $740M, and enterprise value of $1B.
Market Cap Evolution
GoodRx's stock price is $2.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $740M | -1.4% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGoodRx Valuation Multiples
GoodRx trades at 1.3x EV/Revenue multiple, and 3.9x EV/EBITDA.
EV / Revenue (LTM)
GoodRx Financial Valuation Multiples
As of April 14, 2026, GoodRx has market cap of $740M and EV of $1B.
Equity research analysts estimate GoodRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GoodRx has a P/E ratio of 23.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $740M | XXX | $740M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 3.9x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBIT | 5.4x | XXX | 5.2x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| P/E | 23.9x | XXX | 24.3x | XXX | XXX | XXX |
| EV/FCF | 8.8x | XXX | 9.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GoodRx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
GoodRx Margins & Growth Rates
GoodRx's revenue in the last 12 month declined by (1%).
GoodRx's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.9M for the same period.
GoodRx's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GoodRx's rule of X is 21% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
GoodRx Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (1%) | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | (8%) | XXX | (13%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 39% | XXX | 42% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 82% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
GoodRx Public Comps
See public comps and valuation multiples for other Health Benefits & Financial Solutions and Telemedicine & Virtual Care comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| GoodRx | XXX | XXX | XXX | XXX | XXX | XXX |
| CEWE Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Zjamp Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Genky Drug Stores | XXX | XXX | XXX | XXX | XXX | XXX |
| Nerdwallet | XXX | XXX | XXX | XXX | XXX | XXX |
| Apotea | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GoodRx M&A Activity
GoodRx acquired XXX companies to date.
Last acquisition by GoodRx was on XXXXXXXX, XXXXX. GoodRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by GoodRx
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGoodRx Investment Activity
GoodRx invested in XXX companies to date.
GoodRx made its latest investment on XXXXXXXX, XXXXX. GoodRx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by GoodRx
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GoodRx
| When was GoodRx founded? | GoodRx was founded in 2015. |
| Where is GoodRx headquartered? | GoodRx is headquartered in United States. |
| How many employees does GoodRx have? | As of today, GoodRx has over 738 employees. |
| Who is the CEO of GoodRx? | GoodRx's CEO is Wendy Barnes. |
| Is GoodRx publicly listed? | Yes, GoodRx is a public company listed on Nasdaq. |
| What is the stock symbol of GoodRx? | GoodRx trades under GDRX ticker. |
| When did GoodRx go public? | GoodRx went public in 2020. |
| Who are competitors of GoodRx? | GoodRx main competitors are CEWE Group, Zjamp Group, Genky Drug Stores, Nerdwallet. |
| What is the current market cap of GoodRx? | GoodRx's current market cap is $740M. |
| What is the current revenue of GoodRx? | GoodRx's last 12 months revenue is $788M. |
| What is the current revenue growth of GoodRx? | GoodRx revenue growth (NTM/LTM) is (1%). |
| What is the current EV/Revenue multiple of GoodRx? | Current revenue multiple of GoodRx is 1.3x. |
| Is GoodRx profitable? | Yes, GoodRx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GoodRx? | GoodRx's last 12 months EBITDA is $261M. |
| What is GoodRx's EBITDA margin? | GoodRx's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of GoodRx? | Current EBITDA multiple of GoodRx is 3.9x. |
| What is the current FCF of GoodRx? | GoodRx's last 12 months FCF is $116M. |
| What is GoodRx's FCF margin? | GoodRx's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of GoodRx? | Current FCF multiple of GoodRx is 8.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.